Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis: a Multicentre Randomized Controlled Clinical Trial

5-Fluorouracil (5FU) is proven to be the most effective therapy in field directed treatment for AK, with Jansen et al. reporting a 1-year probability of treatment success of 74.7%. However, treatment with 5FU is associated with side effects, like erythema, itching, a burning sensation and crusting, and a burdensome dosing regimen of twice daily application for four weeks. This long treatment duration in combination with side-effects and overall lifestyle adjustments during treatment can be the reason for poor adherence and premature termination, and it can also lead to future refusal of 5FU therapy. Therefore, room for improvement lies in increasing the tolerability, in terms of side effects or treatment duration, while maintaining the efficacy of 5FU in the treatment of AK.
Addition therapy, which can shorten the duration of treatment, might be the key to success. Calcipotriol (CAL) enhances thymic stromal lymphopoietin (TSLP), an epithelium-derived cytokine, which promotes antitumor immunity. Therefore, it is known to have a synergistic effect when combined with 5FU in the treatment of AK. This suggests that short-term treatment with 5FU-CAL is effective and provides the opportunity to shorten duration of treatment, thereby improving tolerability of treatment and full adherence to the treatment regimen.
However, no study compared 5FU-CAL combination therapy with standard 5FU treatment for a duration of 28 days. This study aims to evaluate whether a short course of combination therapy with 5FU-CAL is non-inferior to a full course of 5FU monotherapy with respect to the 1-year probability of treatment success.

开始日期2024-09-04

申办/合作机构-

NCT05699603 / Recruiting临床2期IIT

Phase IIA, Single-Arm, Open- Label, Clinical Trial of Calcipotriene Plus 5-fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients

This phase IIA study evaluates the effects of calcipotriene plus 5- fluorouracil immunotherapy for skin cancer prevention in organ transplant recipients. Precancerous skin lesions, actinic keratoses (AK), may put organ transplant recipients at higher than average risk of developing skin cancer. Topical calcipotriene is a form of vitamin D and is used to treat psoriasis and topical 5- fluorouracil is a chemotherapy agent applied to the skin. The combination of calcipotriene plus 5- fluorouracil topical cream, which activates the immune cells against cancer, may help prevent skin cancer in organ transplant recipients who have precancerous skin lesions.

开始日期2024-07-02

申办/合作机构

University of Arizona

[+1]

CTRI/2024/01/061889 / Not yet recruiting临床3期

Comparative Evaluation of Vishataila & its modified form as an ointment with Calcipotriol ointment (0.005%) in the treatment of Dushivishjanya Kitibha Kushtha (Chronic Plaque Psoriasis). - NIL

开始日期2024-02-01

申办/合作机构

Mahatma Gandhi Ayurved College Hospital & Research Centre

100 项与卡泊三醇相关的临床结果

登录后查看更多信息

100 项与卡泊三醇相关的转化医学

登录后查看更多信息

100 项与卡泊三醇相关的专利（医药）

登录后查看更多信息

1,560

项与卡泊三醇相关的文献（医药）

2024-12-31·The Journal of dermatological treatment

Comparison of various excimer laser (EL) combination therapies for vitiligo: a systematic review and network meta-analysis

Review

作者: Li, XinHong ; Sun, Xiao ; Mu, ZengYi ; Shi, Lei ; Wang, XinYue ; Hu, Yue ; Li, ChanXiu ; Wang, YaPing

AIM:

This study aimed to compare the efficacy and safety of excimer laser (EL)-based combination regimens in improving repigmentation.

METHODS:

A comprehensive search was conducted in PubMed, Web of Science, Cochrane Library, and Embase on July 1, 2023, to include randomized controlled trials of EL combination treatments for vitiligo that met the criteria. The primary outcome measure was a repigmentation rate ≥ 75%, and the secondary outcome measures were a repigmentation rate of ≤ 25% and adverse events.

RESULTS:

Eleven studies involving 348 patients were included. Network Meta-Analysis showed that EL combined with antioxidants (SUCRA = 98.8%), EL combined with calcipotriol (SUCRA = 59.8%) and EL combined with tacalcitol (SUCRA = 59.6%) were the three optimal interventions achieving repigmentation rates ≥ 75%. EL alone (SUCRA = 77.6%), EL combined with tacalcitol (SUCRA = 61.7%) and EL combined with antioxidants (SUCRA = 57.2%) were the three interventions with the highest rates of treatment failure. Adverse events in all groups mainly included erythema, burning sensation and hyperpigmentation. Based on the results of the current study, EL combination therapies were safe with mild adverse events.

CONCLUSION:

EL combined with antioxidants was the preferred regimen for vitiligo, whereas EL alone was the regimen with the highest rate of treatment failure in vitiligo.

2024-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey

Article

作者: López Estebaranz, José Luis ; Kurzen, Hjalmar ; Galván, Jordi

BACKGROUND:

Psoriasis significantly impacts patients' quality of life (QoL). Dissatisfaction and non-adherence are major barriers associated with topical treatments. A cream based on the polyaphron dispersion (PAD) Technology containing a fixed-dose of calcipotriol (CAL) and betamethasone dipropionate (BDP) was designed for a patient-friendly psoriasis management. The CAL/BDP PAD-cream demonstrated efficacy, convenience, and safety/tolerability in clinical trials.

OBJECTIVES:

This research assesses the real-world use, perception, satisfaction, and adherence of CAL/BDP PAD-cream among plaque psoriasis patients.

METHODS:

Between September-November 2023, psoriasis patients from Spain and Germany using or having used CAL/BDP PAD-cream for >2 weeks were recruited via Wefight network to complete a 30-questions online survey. Anonymized results were pooled for descriptive statistical analysis.

RESULTS:

The survey was completed by 129 patients (mean age: 43 years; 66% females; mean psoriasis duration: 12 years). Most patients (93%) were satisfied with CAL/BDP PAD-cream. The 66% reported high adherence (visual analogue scale 80-100) and 91% preferred CAL/BDP PAD-cream to their previous topical(s). Patients highlighted its ease/convenience of application, tolerability, and lack of itching/burning.

CONCLUSIONS:

Psoriasis patients treated with CAL/BDP PAD-cream in a real-world setting show high satisfaction, good adherence, and a positive perception of the product, suggesting that favorable outcomes observed in clinical trials translate to real clinical practice.

2024-12-01·Current computer-aided drug design

Network Pharmacology, Molecular Docking and Experimental Verification Revealing the Mechanism of Fule Cream against Childhood Atopic Dermatitis

Article

作者: Gao, Ying ; Qi, Yuenan ; Guan, Jing ; Ou, Ling ; Liu, Yuxin ; Zhang, Jianmin ; Liu, Chang ; Liu, Yi ; Lv, Xiaoxi

Background::

The Fule Cream (FLC) is an herbal formula widely used for the treatment of pediatric atopic dermatitis (AD), however, the main active components and functional mechanisms of FLC remain unclear. This study performed an initial exploration of the potential acting mechanisms of FLC in childhood AD treatment through analyses of an AD mouse model using network pharmacology, molecular docking technology, and RNA-seq analysis.

Materials and Methods::

The main bioactive ingredients and potential targets of FLC were collected from the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) and SwissTargetPrediction databases. An herb-compound-target network was built using Cytoscape 3.7.2. The disease targets of pediatric AD were searched in the DisGeNET, Therapeutic Target Database (TTD), OMIM, DrugBank and GeneCards databases. The overlapping targets between the active compounds and the disease were imported into the STRING database for the construction of the protein-protein interaction (PPI) network. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of the intersection targets were performed, and molecular docking verification of the core compounds and targets was then performed using AutoDock Vina 1.1.2. The AD mouse model for experimental verification was induced by MC903.

Results::

The herb-compound-target network included 415 nodes and 1990 edges. Quercetin, luteolin, beta-sitosterol, wogonin, ursolic acid, apigenin, stigmasterol, kaempferol, sitogluside and myricetin were key nodes. The targets with higher degree values were IL-4, IL-10, IL-1α, IL-1β, TNFα, CXCL8, CCL2, CXCL10, CSF2, and IL-6. GO enrichment and KEGG analyses illustrated that important biological functions involved response to extracellular stimulus, regulation of cell adhesion and migration, inflammatory response, cellular response to cytokine stimulus, and cytokine receptor binding. The signaling pathways in the FLC treatment of pediatric AD mainly involve the PI3K-Akt signaling pathway, cytokine‒cytokine receptor interaction, chemokine signaling pathway, TNF signaling pathway, and NF-κB signaling pathway. The binding energy scores of the compounds and targets indicate a good binding activity. Luteolin, quercetin, and kaempferol showed a strong binding activity with TNFα and IL-4.

Conclusion::

This study illustrates the main bioactive components and potential mechanisms of FLC in the treatment of childhood AD, and provides a basis and reference for subsequent exploration.

项与卡泊三醇相关的新闻（医药）

2024-10-01

·医药地理

信达生物1类抗体新药上市申报 | 银屑病治疗市场全景分析

银屑病，也被广泛称为“牛皮癣”，是一种常见的多基因遗传性皮肤疾病，常表现为局限或广泛分布的鳞屑性红斑或斑块。在中国，据不完全统计，银屑病的发病率约为0.47%，约有650万患者。全球范围内，根据2016年世界卫生组织（WHO）的数据，约有1.25亿人受银屑病影响。银屑病不单是一种皮肤病，它还包含全身性的炎症过程，因此被归类为系统性疾病。虽然早期研究一直聚焦于角质形成细胞的作用，但近期的发现表明，活化的T细胞，特别是Th1、Th2和Th17细胞的激活与相互作用，才是银屑病发病的核心机制。得益于这些研究成果，银屑病的治疗实现了突破性进展。特别是生物制剂的应用，它们在靶向治疗银屑病方面取得了显著成就。 9月26日，中国国家药监局药品审评中心（CDE）官网最新公示，信达生物1类新药匹康奇拜单抗注射液上市申请获得受理。匹康奇拜单抗（研发代号：IBI112）是由信达生物研发的一款重组抗白介素23p19亚基（IL-23p19）抗体。在2024年5月，信达生物宣布，该产品在中国中重度斑块状银屑病患者中进行的3期临床研究CLEAR-1中，成功达到了主要终点和所有关键次要终点。研究结果显示，接受匹康奇拜单抗治疗的患者中，有超过80%的受试者在16周治疗后达到了PASI 90（银屑病面积和严重程度指数改善90%以上）。此外，该药物还展现了长期疗效维持和季度给药间隔的优势，即在维持期内，患者可每12周接受一次给药，预计年度给药次数仅需5至6次。生物制品占据抗银屑病用药的主要市场根据PDB药物综合数据库国内全渠道放大数据显示，抗银屑病用药的生物制品市场金额增长迅猛，从2020年的7.79亿元增长至2023年的51.43亿元，以87%的份额占据抗银屑病用药的主要市场。化学药品的市场金额变化趋势较为平缓，基本没有太大的变化，2023年总销售额达到7.96亿元，占比总市场份额的13%。图1：2020-2024（Q1）抗银屑病生物制品市场金额变化趋势数据来源：PDB药物综合数据库-国内全渠道放大数据，中国医药工业信息中心图2：2020-2024（Q1）抗银屑病化学药品市场金额变化趋势数据来源：PDB药物综合数据库-国内全渠道放大数据，中国医药工业信息中心生物制品中的各产品占比情况 2023年，在抗银屑病用药生物制品中，司库奇尤单抗以73.19%的市场份额稳居首位，其总销售额达到了37.64亿元。乌司奴单抗以17.06%的市场份额位居第二，总销售额为8.78亿元。紧随其后的是依奇珠单抗、古塞奇尤单抗、佩索利单抗和抗人IL-8单克隆抗体，这些生物制品在银屑病治疗领域均展现了显著的疗效和市场潜力。随着生物制剂的不断研发和应用，预计银屑病治疗市场将持续扩大，为患者提供更多的治疗选择。图3：2020-2024（Q1）抗银屑病生物制剂产品通用名变化趋势数据来源：PDB药物综合数据库-国内全渠道放大数据，中国医药工业信息中心化学药品中的各产品占比情况 2023年，在抗银屑病用药化学药品中，卡泊三醇以44.75%的市场份额领跑，创下3.56亿元的销售额。卡泊三醇与倍他米松的复方制剂也表现不俗，市场占有率为27.68%，销售额达到2.22亿元。此外，本维莫德、阿维A、他卡西醇等药物也在市场中占有一席之地。图4：2020-2024（Q1）抗银屑病化学药品产品通用名变化趋势数据来源：PDB药物综合数据库-国内全渠道放大数据，中国医药工业信息中心小结抗银屑病用药市场正在快速增长，主要得益于新型生物制剂和药物的不断推出，为患者提供了更多样化的治疗选择。但这一增长同时带来了挑战，包括治疗费用的高昂给患者带来的经济压力、患者依从性问题、市场竞争的加剧、新药市场准入和医保覆盖的复杂性，以及对个体化治疗需求的增加。为了解决这些问题，未来还需要各方面的合作，包括通过临床研究和药物经济学评估来提高药物的可及性和可负担性，同时通过政策改革和市场推广来提高患者的依从性和治疗效果。 END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

上市批准临床3期申请上市

2024-09-30

·Pharmaceutical Technology

LEO Pharma announces Enstilar NDA submission for plaque psoriasis in China

The review process is set for completion in H1 2026. Credit: Hriana via Shutterstock. Leo Pharma has submitted a New Drug Application (NDA) to China’s National Medical Products Administration for Enstilar, targeting the treatment of adult patients with plaque psoriasis. Enstilar is an aerosol spray foam combining calcipotriol and betamethasone, designed to improve upon the existing Daivobet ointment, which is currently a standard treatment in China. The submission follows a series of milestones for LEO Pharma in the EU and the US, with China potentially becoming the largest market for Enstilar. The NDA is supported by a Phase III trial involving 604 adult Chinese subjects with stable plaque psoriasis. This trial showed Enstilar to be superior to Daivobet ointment, achieving both primary and secondary endpoints. See Also: FDA approves PureTech’s KarXT to treat schizophrenia in adults FDA greenlights Regeneron’s Dupixent for the treatment of COPD The Center for Drug Evaluation (CDE) in China will now validate and fully evaluate the NDA. The regulatory review process is anticipated to be completed in the first half (H1) of 2026. LEO Pharma China general manager Byron Yin said: “LEO Pharma strives to enhance patient care and elevate quality of life for those living with complex skin conditions like plaque psoriasis. “Today’s submission is a crucial step towards offering a much-needed new treatment option in our region, in addition to the existing portfolio offering from LEO Pharma China.” Enstilar is already indicated in the EU for up to four weeks of treatment for psoriasis vulgaris in adults, with suitable candidates eligible for long-term maintenance. Recently, the European Commission authorised Leo Pharma’s Anzupgo cream for treating adults with moderate to severe chronic hand eczema .

临床3期申请上市临床结果上市批准

2024-09-27

·Business Wire

LEO Pharma Submits New Drug Application for Enstilar® for Adults with Plaque Psoriasis in China

BALLERUP, Denmark--( BUSINESS WIRE )-- NOT INTENDED FOR DISTRIBUTION IN THE UK LEO Pharma A/S, a global leader in medical dermatology, has today announced its submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA) for Enstilar ® (LEO 90100) to treat adult patients living with plaque psoriasis. Following a week of significant LEO Pharma treatment and data milestones in the EU and the U.S., today’s news of the NDA submission in China is the latest example of LEO Pharma’s global strategy in action across medical dermatology. If approved, China would join 50 other markets in the world to be approved to bring Enstilar to patients, and would be the largest country to date. Enstilar ® , a calcipotriol/betamethasone cutaneous foam, is an improved formulation of Daivobet ® ointment, which is one of the current standard treatment options in China for adults living with plaque psoriasis. 4 Both Daivobet ointment and Enstilar are LEO Pharma products. “ LEO Pharma strives to enhance patient care and elevate quality of life for those living with complex skin conditions like plaque psoriasis ,” said Byron Yin, General Manager for LEO Pharma, China. “ Today’s submission is a crucial step towards offering a much-needed new treatment option in our region, in addition to the existing portfolio offering from LEO Pharma China.” “ Today’s submission of our NDA for Enstilar is a testament to LEO Pharma’s truly global outlook and ambition in advancing dermatology, following on from a week of milestones across both the EU and U.S.” said Becki Morison, Executive Vice President, Global Product Strategy & International Operations for LEO Pharma. “ China is a key market for LEO Pharma, with dermatology growing rapidly in the country and our revenue steadily increasing through a strong performance from our team. We will continue to leverage our extensive dermatology expertise to enhance the treatments we can provide in the region, unwavering in our goal to provide support to those in China that need it most.” The NDA submission is supported by results from a phase 3 trial comparing the efficacy and safety of a once daily application with Enstilar and Daivobet ointment after 4 weeks of treatment in adult Chinese subjects with stable plaque psoriasis (N=604). 1,2 The trial achieved its primary and secondary endpoints, with Enstilar demonstrating superiority to Daivobet ointment. 2 “ The trial showed the potential that Enstilar has to improve the quality of life for millions of Chinese patients living with plaque psoriasis,” said Professor Zhang Jianzhong from Peking University People's Hospital, lead investigator of the phase 3 Enstilar trial. “ Through today’s milestone, we take a step towards new treatment options for the millions that live with plaque psoriasis in the near future.” Following the Enstilar submission, the Centre for Drug Evaluation (CDE) will validate the filing, before the full evaluation of the NDA is conducted by the CDE. The regulatory review process is expected to conclude in the first half of 2026. About Enstilar ® Enstilar ® is an aerosol spray foam containing calcipotriol monohydrate 50 mcg/g and betamethasone dipropionate 0.5 mg/g. In the EU, it is indicated for the treatment of psoriasis vulgaris in adults for up to 4 weeks. Patients who have responded at 4 weeks’ treatment using Enstilar once daily are suitable for long-term maintenance treatment. 4-7 About Psoriasis Psoriasis is a chronic, systemic inflammatory disease that primarily affects the skin in 125 million people worldwide. 8,9 Psoriasis is the result of skin barrier cell proliferation and the activation of cytokines (a family of proteins involved in immune responses) that cause inflammation. 10 About 80% to 90% of patients are affected by plaque psoriasis, the most common clinical form of psoriasis. 11 The symptoms of plaque psoriasis are itchy or painful raised scaly and inflamed plaques. Plaques may appear anywhere on the body, but often appear on the scalp, knees, elbows and torso. 11 About LEO Pharma LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion. References ClinicalTrials.gov. National Library of Medicine (U.S.). A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis. Identifier: NCT05919082. https://clinicaltrials.gov/study/NCT05919082 . LEO Pharma Press Release. LEO Pharma Announces Topline Results of Phase 3 Trial in China for Enstilar® (LEO 90100) Demonstrating Superiority in Adult Chinese Subjects With Stable Plaque Psoriasis. Published: May 04, 2024. Last accessed: Sep 25, 2024. Available at: https://www.businesswire.com/news/home/20240507292614/en/LEO-Pharma-Announces-Topline-Results-of-Phase-3-Trial-in-China-for-Enstilar%C2%AE-LEO-90100-Demonstrating-Superiority-in-Adult-Chinese-Subjects-With-Stable-Plaque-Psoriasis . Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663-667. Zhang, XJ et al., Chin J Dermatol, July 2023, Vol. 56, No. 7, Guideline for the diagnosis and treatment of psoriasis in China (2023 edition) Enstilar ® EU Summary of Product Characteristics July 2022. Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study. J Dermatolog Treat. 2016;27(2):120-127. Leonardi C, et al. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris—a Randomized Phase III Study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468-1477. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60: 643-659. National Psoriasis Foundation. Psoriasis Statistics. Last updated: Dec 21, 2022. Last accessed: Sep 25, 2024. Available at: https://www.psoriasis.org/content/statistics . Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645-653. National Psoriasis Foundation. Plaque Psoriasis. Last updated: Feb 08, 2024. Last accessed: Sep 25, 2024. Available at: https://www.psoriasis.org/plaque/ . MAT-76612 September 2024

临床3期临床结果临床2期申请上市免疫疗法

100 项与卡泊三醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01125	卡泊三醇	D05AX02	DB02300

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
寻常性银屑病	日本	Leo Pharma, Inc.	2000-01-18
斑块状银屑病	美国	LEO Pharma A/S	1993-12-29
银屑病	-	Leo Pharma, Inc.	1990-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


phase 3 (EADV2022)	临床3期	斑块状银屑病	796	Calcipotriene and betamethasone dipropionate cream	糧糧廠選繭選鏇遞製製(製積觸蓋築積鏇憲築窪) = 築築製積顧築範遞膚簾糧構製網積醖製壓製蓋 (遞網鬱膚製壓遞蓋選艱 ) 更多	积极	2022-09-07
				Calcipotriene and betamethasone dipropionate gel	糧糧廠選繭選鏇遞製製(製積觸蓋築積鏇憲築窪) = 窪構鹽顧顧鬱衊餘範構糧構製網積醖製壓製蓋 (遞網鬱膚製壓遞蓋選艱 ) 更多
EADV2022	临床3期	斑块状银屑病	-	Calcipotriene (CAL) and betamethasone dipropionate (BDP) cream	願醖鬱壓淵鹽顧窪積蓋(淵獵夢夢蓋選糧鬱鹹襯) = 願夢鹹壓鑰鏇鑰構構鹹窪鬱齋窪願簾範憲鏇遞 (窪觸壓鬱鏇顧觸網觸襯 ) 更多	-	2022-09-07
				Vehicle	願醖鬱壓淵鹽顧窪積蓋(淵獵夢夢蓋選糧鬱鹹襯) = 淵蓋獵鏇鑰襯鏇淵範獵窪鬱齋窪願簾範憲鏇遞 (窪觸壓鬱鏇顧觸網觸襯 ) 更多
EADV2022	临床3期	头皮银屑病	-	CAL/BDP cream	膚構壓顧襯鏇繭糧觸蓋(鹽鹽觸網築遞膚襯衊網) = 遞鏇壓齋鹽範選窪顧鹽願築壓廠艱餘艱鑰鬱願 (鹹襯積淵齋蓋膚鏇鹹網 ) 更多	-	2022-09-07
				Vehicle cream	膚構壓顧襯鏇繭糧觸蓋(鹽鹽觸網築遞膚襯衊網) = 築鹹範願積襯憲齋積膚願築壓廠艱餘艱鑰鬱願 (鹹襯積淵齋蓋膚鏇鹹網 ) 更多
Pubmed 人工标引	N/A	寻常性银屑病	166	Calcipotriene+LEO90100	壓顧窪廠鹹淵遞蓋膚積(憲壓觸蓋願鑰顧鬱網廠) = 網築製積齋鬱憲鏇憲蓋積獵遞網願膚獵襯鏇襯 (齋憲襯壓鏇築鹽憲簾夢, 3.0) 更多	积极	2022-07-18
EADV2022	N/A	斑块状银屑病	-	Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g aerosol foam	觸網衊鑰壓願鑰襯糧築(壓艱選簾網壓範糧鹹襯) = 願範夢築夢選廠襯遞製鏇衊鬱鹽壓觸鑰選範鑰 (鹽簾獵糧鏇觸鬱築網網 )	-	2022-05-12
				Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g cream	觸網衊鑰壓願鑰襯糧築(壓艱選簾網壓範糧鹹襯) = 衊簾鬱鑰製糧構齋願鹹鏇衊鬱鹽壓觸鑰選範鑰 (鹽簾獵糧鏇觸鬱築網網 )
NCT01694433 (CTgov)	临床2/3期	寻常痤疮	66	Calcipotriene (Calcipotriene Cream)	願艱憲積憲構網構簾範(醖憲憲網淵選簾鏇網簾) = 餘醖築廠遞願艱網蓋積鑰憲壓衊繭鹹憲夢遞積 (繭鬱餘鬱遞遞選範衊鹹, 襯壓艱遞觸壓襯製膚夢 ~ 製艱鬱壓鏇鬱淵觸憲築) 更多	-	2019-05-07
				Placebo (Placebo)	願艱憲積憲構網構簾範(醖憲憲網淵選簾鏇網簾) = 窪顧窪餘醖憲鑰鑰遞願鑰憲壓衊繭鹹憲夢遞積 (繭鬱餘鬱遞遞選範衊鹹, 鹽衊觸鬱襯夢構窪齋蓋 ~ 築觸選襯簾觸願膚齋鑰) 更多
NCT02411643 (CTgov)	早期临床1期	局部硬皮病	2	topical calcipotriene 0.005% ointment	餘獵遞鹹觸鹹觸糧簾遞(顧淵襯淵觸壓繭鬱遞艱) = 糧鹹獵構製網鹹襯構淵製顧選廠構製膚蓋淵構 (鬱網選構衊艱蓋齋蓋蓋, 構範糧艱遞繭積願觸壓 ~ 構鏇願齋餘廠鏇壓獵築) 更多	-	2018-09-13
NCT01745133 (CTgov)	临床4期	斑块状银屑病	63	Vehicle Foam	網鏇壓構構壓獵餘淵鑰(鏇網窪獵憲選鏇醖繭構) = 齋遞衊願繭遞廠艱醖築淵願鬱製製膚願衊鹹鏇 (鏇獵蓋網構醖憲艱艱衊, 觸壓築網願獵醖鏇觸膚 ~ 鹹糧構壓衊積襯簾齋製) 更多	-	2016-11-17
NCT00689481 \| NCT00688519 (Pubmed \| Am J Clin Dermatol)	临床3期	斑块状银屑病	-	Calcipotriene 0.005% foam	網製繭艱繭鹹製遞鏇觸(製淵壓壓積鏇構壓餘夢) = 鏇襯積衊網鬱艱選鬱製淵構襯積膚繭繭艱廠襯 (鏇築餘壓願築糧衊鏇鹹 )	-	2012-08-01
				Vehicle foam	網製繭艱繭鹹製遞鏇觸(製淵壓壓積鏇構壓餘夢) = 製衊鏇鹹鹽範遞製遞遞淵構襯積膚繭繭艱廠襯 (鏇築餘壓願築糧衊鏇鹹 )
NCT01139580 (CTgov)	临床3期	银屑病	363	Calcipotriene Foam (Calcipotriene Foam)	淵鑰繭襯廠廠遞窪蓋膚(獵醖獵糧醖選齋壓鏇襯) = 繭遞築醖衊膚憲艱鬱觸積夢廠構網餘憲艱觸壓 (襯鑰壓壓鏇窪製窪鏇簾, 願餘鑰選淵繭範膚衊襯 ~ 築淵襯淵鹽鏇艱壓選襯) 更多	-	2011-09-23
				Vehicle Foam (Vehicle Foam)	淵鑰繭襯廠廠遞窪蓋膚(獵醖獵糧醖選齋壓鏇襯) = 艱範願膚積築範遞襯蓋積夢廠構網餘憲艱觸壓 (襯鑰壓壓鏇窪製窪鏇簾, 憲鑰鹹鑰積網鏇製範餘 ~ 鹹襯餘壓獵壓顧艱鏇餘) 更多